Gene signature may forecast chemo response in sarcoma patients
NCT ID NCT02789384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a genetic test called CINSARC can predict how well chemotherapy works in people with soft-tissue sarcoma. Researchers will collect tumor and blood samples from 205 participants before they receive standard chemotherapy and surgery. The goal is to see if the CINSARC signature matches how the tumor responds, which could help personalize treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict which sarcoma patients will benefit from chemotherapy before surgery.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and the genetic signature may not prove reliable enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HM _ Hôpital de la Timone
RECRUITINGMarseille, 13385, France
-
Centre Georges François Leclerc
RECRUITINGDijon, 21079, France
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
-
Centre Oscar Lambret
NOT_YET_RECRUITINGLille, 59020, France
-
Institut Bergonié
RECRUITINGBordeaux, 33076, France
-
Institut Claudius Regaud - IUCT-0
RECRUITINGToulouse, 31052, France
-
Institut Curie
NOT_YET_RECRUITINGParis, 75005, France
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94805, France
-
Institut Paoli Calmettes
RECRUITINGMarseille, 13273, France
-
Institut de Cancérologie de l'Ouest
RECRUITINGNantes, 44805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Experimental procedure aims to shrink untreatable childhood tumors
- New cocktail of four drugs targets tough sarcomas in kids
- Could a shorter radiation zap before surgery be just as good for sarcoma patients?
- New drug combo shows promise for Hard-to-Treat sarcomas
- New hope for sarcoma patients: immunotherapy plus chemo shows promise